FDA Autism Meeting: Will It Stray From Symptoms And Treatments To Causation?
Executive Summary
US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.
You may also be interested in...
Misinformation Prompted Six Court Cases Against EU COVID-19 Vaccine Approvals In 2021
The EU’s conditional approval of four COVID-19 vaccines and its decision to extend the use of Pfizer/BioNTech’s Comirnaty to a younger age group were challenged in the court last year but the cases were declared inadmissible.
Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.
‘He Is Very Pro-Vaccine’: Trump Mulls RFK Jr. To Chair Commission On Safety
Kennedy Jr. has been a long-time proponent of the view that vaccines are a cause of neurological diseases like autism, despite scientific research that has debunked those claims.